Vyome secures exclusive license from Impetis for selective JAK inhibitor programs
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
Subscribe To Our Newsletter & Stay Updated